Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on Urogen Pharma, with eight buy ratings, one hold, and one sell. The average 12-month price target is $52.38, with recent targets ranging from $56 to $60.
• Urogen reported quarterly revenue of $72.46 million, exceeding the $63.55 million consensus estimate, but its loss of $0.28 per share was wider than expected. Analysts forecast a full-year loss of $0.20 per share.
• Insiders sold 65,269 shares worth approximately $3.04 million over the past quarter, while institutional investors and hedge funds own 91.29% of the stock. URGN recently traded at $36.83, below its 50-day average of $43.82 but above its 200-day average of $34.71.

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $52.38.

Several equities analysts recently issued reports on URGN shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research note on Friday, July 17th. Jefferies Financial Group restated a "buy" rating and set a $56.00 target price on shares of Urogen Pharma in a research report on Thursday, September 10th. Guggenheim lifted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. UBS Group reaffirmed a "buy" rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Finally, TD Cowen boosted their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, August 5th.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 871 shares of the company's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares in the company, valued at approximately $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Chris Degnan sold 2,202 shares of the company's stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the transaction, the chief financial officer owned 4,561 shares of the company's stock, valued at $167,343.09. The trade was a 32.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 65,269 shares of company stock worth $3,037,646 over the last quarter. 4.80% of the stock is currently owned by insiders.

Institutional Trading of Urogen Pharma

Hedge funds have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd acquired a new position in Urogen Pharma during the second quarter worth approximately $66,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the second quarter worth approximately $78,000. Glenmede Trust Co. NA purchased a new position in Urogen Pharma during the first quarter worth approximately $189,000. The Manufacturers Life Insurance Company acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $412,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $431,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $36.83 on Monday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -18.60 and a beta of 1.57. The firm has a 50-day moving average price of $43.82 and a 200 day moving average price of $34.71. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. As a group, research analysts predict that Urogen Pharma will post -0.20 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company's platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen's lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.